. Author manuscript; available in PMC: 2023 Jun 6.

Published in final edited form as: Sci Transl Med. 2023 Apr 19;15(692):eade9078. doi: 10.1126/scitranslmed.ade9078

Table 3.

Mediation effect estimates for quantitative D29 nAb markers with 95% CIs.

Antibody marker(s)	Direct VE	Indirect VE	Proportion Mediated
D29 LV-MN₅₀	84.2% (76.5, 89.3%)	53.3% (36.4, 65.7%)	29.2% (17.2, 41.2%)
D29 PsV-nAb ID₅₀^*	56.0% (42.2, 66.5%)	83.2% (76.9, 87.8%)	68.5% (58.5, 78.4%)
D29 PsV-nAb ID₅₀ + D29 LV-MN₅₀	62.0% (50.0, 71.1%)	80.6% (73.3, 85.8%)	62.9% (52.9, 72.8%)

D29 PsV-nAb ID₅₀ mediation effect point estimates were previously published [table S9 of (10)] and are included here for comparison.

Direct vaccine efficacy (VE) indicates VE comparing vaccine versus placebo with marker set to the value of placebo recipients (undetectable). Indirect VE indicates VE in vaccinated participants comparing observed marker versus hypothetical marker under placebo (undetectable). Proportion mediated indicates the fraction of total risk reduction from vaccine (overall 92.3% VE) attributed to the antibody marker(s) computed as 1 – log(1 – indirect VE/100)/log(1 – total VE/100).